arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Lexeo Therapeutics, Inc.

LXEO

$4.80 ▲ +0.24 (+5.26%) at close

5 Visible periods

21 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Lexeo Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $257.5M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -44.3% ↗

FCF / Share $-1.84 ↗

Trailing P/E —

Price / Book 1.4x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

5-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-99.96M

↓ -1.7% —

FCF / Share Free cash flow per share

$-1.84

↑ +28.2% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Financial Health ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
EPS Growth YoY (%)	39.8% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	75.1% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	65.9% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-1.7% Weak ↑ Weak Improving Year-over-year change in net income	-48.1% Weak Weak Year-over-year change in net income	-12.0% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	28.2% Excellent ↓ Excellent Declining Year-over-year change in free cash flow	76.9% Excellent Excellent Year-over-year change in free cash flow	67.1% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Effective Tax Rate (%) (%)	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—
FCF / Net Income (x)	0.99x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Return on Invested Capital (%)	-44.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-90.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-47.7% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	42.3% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-40.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-72.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-49.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-62.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-40.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-370%)	-84.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-661%)	-58.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-490%)	52.5% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+250%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Interest Coverage (x)	-1050.55x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-832.80x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-334.21x Weak Weak Operating income divided by interest expense Optimal: > 5x	-664.93x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-63.00M	$-35.01M	$-121.47M	$-77.33M	$-135.86M

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Revenue per Share (USD)	—	—	—	$0.40	—
Basic EPS, GAAP (USD)	$-1.86	$-3.09	$-12.40	$-36.36	—
Free Cash Flow per Share (USD)	$-1.84	$-2.57	$-11.13	$-33.88	—
Book Value per Share (USD)	$3.38	$3.53	$4.26	$-70.28	—
Tangible Book Value per Share (USD)	$3.38	$3.53	$4.26	$-70.28	—
Basic Weighted Avg Shares (shares)	53.65M	31.79M	5.35M	1.63M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Working Capital (USD)	$171.58M	$103.28M	$107.06M	$65.70M	—
Total Equity (USD)	$246.67M	$116.84M	$113.53M	$-112.95M	$-55.60M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	$654.00K	—
Net Income, GAAP (USD)	$-99.96M	$-98.33M	$-66.39M	$-59.28M	—
Operating Cash Flow (USD)	$-98.56M	$-81.15M	$-59.50M	$-54.56M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 18 quarters

Lexeo Therapeutics, Inc.

Analytical Summary

5-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare LXEO with peers